非瓣膜性房颤患者的卒中风险评分系统比较
Comparison of Stroke Risk Scoring Systems in Patients with Non-Valvular Atrial Fibrillation
DOI: 10.12677/ACM.2023.1361369, PDF,   
作者: 易 鑫, 杨 仙, 杨 敏, 崔 犇, 殷跃辉*：重庆医科大学附属第二医院心血管内科，重庆；刘宇行：重庆医科大学附属第二医院感染科，重庆；周凡涵：重庆医科大学附属第二医院急诊科，重庆
关键词: 房颤；卒中；CHADS2评分；CHA2DS2-VASc评分；CHA2DS2-VA评分；Atrial Fibrillation； Stroke； CHADS2 Score； CHA2DS2-VASc Score； CHA2DS2-VA Score
摘要: 对于非瓣膜性房颤患者的卒中风险评估目前有三个评分系统，分别为CHADS2评分、CHA2DS2-VASc评分和非性别相关的CHA2DS2-VA评分。借助卒中风险评分对NVAF患者进行危险分层，可以权衡预防血栓带来的益处和抗凝治疗后增加出血风险的弊端。识别非瓣膜性房颤患者卒中风险危险人群，并对危险人群进一步分层，对临床上是否实行抗凝治疗尤为重要。对于卒中风险的评估逐步精准化，是基于对卒中的危险因素认识的深入，房颤患者卒中风险评分有利于为患者制定个体化的抗凝治疗方案。本文分别对上述三种卒中风险评分的诞生、优势与不足方面做一综述，寻找适合中国人的评分体系。
Abstract: There are currently three scoring systems for stroke risk assessment in patients with nonvalvular atrial fibrillation, namely the CHADS2 score, the CHA2DS2-VASc score, and the non-sex-related CHA2DS2-VA score. Stroke risk scores are now needed for risk stratification in patients with NVAF, balancing the benefit of thromboprophylaxis against the downside of increased bleeding risk with anticoagulation. How to identify the risk population of stroke in patients with non-valvular atrial fi-brillation and how to further stratify the risk population is particularly important for the imple-mentation of anticoagulant therapy in clinical practice. The gradually accurate assessment of stroke risk is based on the in-depth understanding of the risk factors of stroke. The stroke risk score for patients with atrial fibrillation is conducive to the development of individualized anticoagulation therapy for patients. This article reviews the birth, advantages and disadvantages of the above three stroke risk scores.
文章引用：易鑫, 刘宇行, 杨仙, 杨敏, 崔犇, 周凡涵, 殷跃辉. 非瓣膜性房颤患者的卒中风险评分系统比较[J]. 临床医学进展, 2023, 13(6): 9780-9788. https://doi.org/10.12677/ACM.2023.1361369

参考文献

[1] Anderson, D.C., Halperin, J.L., Hart, R.G., Mcanulty, J.H. and Sherman, D.G. (1998) Patients with Nonvalvular Atrial Fibrillation at Low Risk of Stroke during Treatment with Aspirin—Stroke Prevention in Atrial Fibrillation III Study. JAMA: The Journal of the American Medical Association, 279, 1273-1277. [Google Scholar] [CrossRef] 
[2] Lip, G., Lip, G.Y.H., Freedman, B., Caterina, R.D. and Potpara, T.S. (2017) Stroke Prevention in Atrial Fibrillation: Past, Present and Future. Comparing the Guidelines and Practical Deci-sion-Making. Thrombosis & Haemostasis, 117, 1230-1239. [Google Scholar] [CrossRef] 
[3] Lega, J.C., Bertoletti, L., Gremillet, C., Chapelle, C. and Laporte, S. (2014) Consistency of Safety and Efficacy of New Oral Anti-coagulants across Subgroups of Patients with Atrial Fibrillation. PLOS ONE, 9, e91398. [Google Scholar] [CrossRef] [PubMed]
[4] Ji, C., Wu, S., Shi, J., Huang, Z., Chen, S., Wang, G. and Cui, W. (2020) Baseline CHADS2 Score and Risk of Cardiovascular Events in the Population without Atrial Fibrillation. American Journal of Cardiology, 129, 30-35. [Google Scholar] [CrossRef] [PubMed]
[5] Lévy, S., Steinbeck, G., Santini, L., Nabauer, M., Maceda, D.P., Kantharia, B.K., Saksena, S. and Cappato, R. (2022) Management of Atrial Fibrillation: Two Decades of Progress—A Scientific Statement from the European Cardiac Arrhythmia Society. Journal of Interventional Cardiac Electrophysiology, 65, 287-326. [Google Scholar] [CrossRef] [PubMed]
[6] Ukaji, T., Ishikawa, T., Nakamura, H., Mizutani, Y., Yamada, K., Shimura, M., Kondo, Y., Tamura, Y., Koshikawa, Y., Hisauchi, I., Nakahara, S., Itabashi, Y., Kobayashi, S. and Taguchi, I. (2023) Prognostic Impacts of CHADS2, CHA2DS2-VASc, and CHA2DS2-VASc-HS Scores on Clinical Outcomes after Elective Drug-Eluting Stent Placement for De Novo Coronary Stenosis. Circulation Reports, 5, 123-132. [Google Scholar] [CrossRef] 
[7] Investigators AF (1994) Risk Factors for Stroke and Efficacy of Antithrombotic Therapy in Atrial Fibrillation. Analysis of Pooled Data from Five Randomized Controlled Trials. Archives of Internal Medicine, 154, 1449-1457. [Google Scholar] [CrossRef] 
[8] Hart, R., Pearce, L., McBride, R., Rothbart, R. and Asinger, R. (1999) Factors Associated with Ischemic Stroke during Aspirin Therapy in Atrial Fibrillation: Analysis of 2012 Participants in the SPAF I-III Clinical Trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke, 30, 1223-1229. [Google Scholar] [CrossRef] 
[9] Gage, B.F., Waterman, A.D., Shannon, W., Boechler, M., Rich, M.W. and Radford, M.J. (2001) Validation of Clinical Classification Schemes for Predicting Stroke: Results from the National Registry of Atrial Fibrillation. ACC Current Journal Review, 10, 20-21. [Google Scholar] [CrossRef] 
[10] Gage, B., van Walraven, C., Pearce, L., et al. (2004) Select-ing Patients with Atrial Fibrillation for Anticoagulation: Stroke Risk Stratification in Patients Taking Aspirin. Circulation, 110, 2287-2292. [Google Scholar] [CrossRef] 
[11] Fuster, V., Rydén, L., Cannom, D.S., et al. (2006) ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Car-diology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Pa-tients with Atrial Fibrillation): Developed in Collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. European Heart Journal, 38, 1231-1265. [Google Scholar] [CrossRef] 
[12] Coppens, M., Eikelboom, J., Hart, R., et al. (2013) The CHA2DS2-VASc Score Identifies Those Patients with Atrial Fibrillation and a CHADS2 Score of 1 Who Are Un-likely to Benefit from Oral Anticoagulant Therapy. European Heart Journal, 34, 170-176. [Google Scholar] [CrossRef] [PubMed]
[13] 历治潼, 赵玫. CHADS2评分及其衍生评分对冠状动脉病变严重程度的预测价值[J]. 山东医药, 2019, 59(4): 6-9.
[14] Borre, E.D., Goode, A., Raitz, G., Shah, B. and Sanders, G.D. (2018) Predicting Thromboembolic and Bleeding Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Sys-tematic Review. Thrombosis and Haemostasis, 118, 2171-2187. [Google Scholar] [CrossRef] [PubMed]
[15] Olesen, J.B., Torp-Pedersen, C., Hansen, M.L. and Lip, G. (2012) The Value of the CHA2DS2-VASc Score for Refining Stroke Risk Stratification in Patients with Atrial Fibrillation with a CHADS2 Score 0-1: A Nationwide Cohort Study. Thrombosis and Haemostasis, 107, 1172-1179. [Google Scholar] [CrossRef] 
[16] Camm, A.J., Kirchhof, P., Savelieva, I., et al. (2010) Guidelines for the Management of Atrial Fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European Heart Journal, 31, 2369-2429.
[17] National Collaborating Centre for Chronic Conditions (UK) (2006) Atrial Fibrillation: National Clinical Guideline for Management in Primary and Secondary Care. Clinical Medicine, 7, 379.
[18] Singer, D.E., Albers, G.W., Dalen, J.E., et al. (2008) Antithrombotic Therapy in Atrial Fibrilla-tion: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 133, 546S-592S.
[19] Wang, T.J., et al. (2003) A Risk Score for Predicting Stroke or Death in Individuals with New-Onset Atrial Fibrillation in the Community. The Framingham Heart Study. ACC Current Journal Review, 12, 54. [Google Scholar] [CrossRef] 
[20] Deirdre, L. and Gregory, L. (2009) Female Gender Is a Risk Factor for Stroke and Thromboembolism in Atrial Fibrillation Patients. Thrombosis & Haemostasis, 102, 802-805. [Google Scholar] [CrossRef] 
[21] Fang, M.C. (2005) Gender Differences in the Risk of Ischemic Stroke and Peripheral Embolism in Atrial Fibrillation: The Anticoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. Circulation, 112, 1687-1691. [Google Scholar] [CrossRef] 
[22] Lip, G., Nieuwlaat, R., Pisters, R., Lane, D. and Crijns, H. (2010) Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach: The Euro Heart Survey on Atrial Fibrillation. Chest, 137, 263-272. [Google Scholar] [CrossRef] [PubMed]
[23] Hart, R., Pearce, L., Halperin, J. and Miller, V. (1994) Aspirin in El-derly Atrial Fibrillation Patients. Stroke, 25, 1525-1526. [Google Scholar] [CrossRef] 
[24] Friberg, L., Benson, L., Rosenqvist, M. and Lip, G. (2012) Assessment of Female Sex as a Risk Factor in Atrial Fibrillation in Swe-den: Nationwide Retrospective Cohort Study. BMJ (Clinical Research ed), 344, e3522. [Google Scholar] [CrossRef] [PubMed]
[25] Avgil Tsadok, M., Jackevicius, C., Rahme, E., Humphries, K., Behlouli, H. and Pilote, L. (2012) Sex Differences in Stroke Risk among Older Patients with Recently Diagnosed Atrial Fibrillation. JAMA, 307, 1952-1958. [Google Scholar] [CrossRef] [PubMed]
[26] Nielsen, P., Skjøth, F., Overvad, T., Larsen, T. and Lip, G. (2018) Female Sex Is a Risk Modifier Rather than a Risk Factor for Stroke in Atrial Fibrillation: Should We Use a CHADS2-VA Score Rather than CHA2DS2-VASc? Circulation, 137, 832-840. [Google Scholar] [CrossRef] 
[27] Nielsen, P. and Overvad, T. (2020) Female Sex as a Risk Modifier for Stroke Risk in Atrial Fibrillation: Using CHA2DS2-VASc versus CHA2DS2-VA for Stroke Risk Stratification in Atrial Fibrillation: A Note of Caution. Thrombosis and Haemostasis, 120, 894-898. [Google Scholar] [CrossRef] [PubMed]
[28] Guo, Y., Apostolakis, S., Blann, A., et al. (2013) Validation of Con-temporary Stroke and Bleeding Risk Stratification Scores in Non-Anticoagulated Chinese Patients with Atrial Fibrillation. International Journal of Cardiology, 168, 904-909. [Google Scholar] [CrossRef] [PubMed]
[29] Siu, C., Lip, G., Lam, K. and Tse, H. (2014) Risk of Stroke and Intracranial Hemorrhage in 9727 Chinese with Atrial Fibrillation in Hong Kong. Heart Rhythm, 11, 1401-1408. [Google Scholar] [CrossRef] [PubMed]
[30] Lin, L., Lee, C., Yu, C., et al. (2011) Risk Factors and Incidence of Ischemic Stroke in Taiwanese with Nonvalvular Atrial Fibrillation—A Nation Wide Database Analysis. Atherosclero-sis, 217, 292-295. [Google Scholar] [CrossRef] [PubMed]
[31] Shao, X.H., Yang, Y.M., Zhu, J., Yu, L.T. and Liu, L.S. (2020) Increased Mortality in Patients with Secondary Diagnosis of Atrial Fibrillation: Report from Chinese AF Registry. Annals of Noninvasive Electrocardiology, 25, e12774. [Google Scholar] [CrossRef] [PubMed]
[32] Choi, S., Kim, M., Kim, H., et al. (2022) Validation of the CHA2DS2-VA Score (Excluding Female Sex) in Nonvalvular Atrial Fibrillation Patients: A Nationwide Population-Based Study. Jour-nal of Clinical Medicine, 11, Article No. 1823. [Google Scholar] [CrossRef] [PubMed]
[33] Suzuki, S., Yamashita, T., Okumura, K., et al. (2015) Incidence of Ischemic Stroke in Japanese Patients with Atrial Fibrillation Not Receiving An-ticoagulation Therapy. Circulation Journal, 79, 432-438. [Google Scholar] [CrossRef] 
[34] Abe, H. and Koretsune, Y. (2015) New Modified CHA2DS2-VA Scoring System for Japanese Patients with Non-Valvular Atrial Fibrillation. Circulation Journal: Official Journal of the Japanese Circulation Society, 79, 1682-1684. [Google Scholar] [CrossRef] 
[35] Tomita, H., Okumura, K., Inoue, H., et al. (2015) Validation of Risk Scoring System Excluding Female Sex From CHA2DS2-VASc in Japanese Patients with Nonvalvular Atrial Fibrilla-tion—Subanalysis of the J-RHYTHM Registry. Circulation Journal: Official Journal of the Japanese Circulation Society, 79, 1719-1726. [Google Scholar] [CrossRef] 
[36] Chao, T.F., Joung, B., Takahashi, Y., Lim, T.W., Choi, E.K., Chan, Y.H., Guo, Y., Sriratanasathavorn, C., Oh, S., Okumura, K. and Lip, G.Y.H. (2021) 2021 Focused Update of the 2017 Consensus Guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on Stroke Prevention in Atrial Fibrillation. Journal of Arrhythmia, 37, 1389-1426. [Google Scholar] [CrossRef] [PubMed]
[37] Ono, K., Iwasaki, Y.K., Akao, M., Ikeda, T., et al. (2022) JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias. Journal of Arrhythmia, 38, 833-973. [Google Scholar] [CrossRef] [PubMed]
[38] Cheung, C.C., Nattel, S., Macle, L. and Andrade, J.G. (2021) Management of Atrial Fibrillation in 2021: An Updated Comparison of the Current CCS/CHRS, ESC, and AHA/ACC/HRS Guide-lines. Canadian Journal of Cardiology, 37, 1607-1618. [Google Scholar] [CrossRef] [PubMed]
[39] Doost, A., Alasady, M. and Scott, P. (2019) National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018. Heart Lung & Circulation, 28, e106-e107. [Google Scholar] [CrossRef] [PubMed]
[40] Mulia, E.P.B. (2023) Gender and Atrial Fibrillation: Revisiting Its Role in Integrated ABC Pathway Management. Heart Vessels, 38, 873-875. [Google Scholar] [CrossRef] [PubMed]

为你推荐